[{"id":"694735df-ac85-49ba-93fc-bc6caa6ca10b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05868174","created_at":"2023-05-22T16:05:29.186Z","updated_at":"2025-02-25T16:18:49.188Z","phase":"Phase 1","brief_title":"Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors","source_id_and_acronym":"NCT05868174","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • 177Lu-DOTA-girentuximab (TLX250) • Rencarex (girentuximab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"483965a6-ed6b-4cce-b166-abbe6a657118","acronym":"","url":"https://clinicaltrials.gov/study/NCT05706129","created_at":"2023-05-15T15:04:33.169Z","updated_at":"2024-07-02T16:35:12.345Z","phase":"Phase 1/2","brief_title":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05706129","lead_sponsor":"Debiopharm International SA","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ITM-91"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-03-29"},{"id":"943dda56-e7f0-4946-96ee-d51318451cb0","acronym":"CAMP1","url":"https://clinicaltrials.gov/study/NCT05698238","created_at":"2023-01-26T16:02:19.184Z","updated_at":"2024-07-02T16:35:53.273Z","phase":"Phase 1","brief_title":"Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05698238 - CAMP1","lead_sponsor":"Mabpro, a.s.","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CA9hu-1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-03-15"},{"id":"ba768302-dd29-4250-bc83-4b97e5814f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT00087022","created_at":"2021-01-18T00:15:20.219Z","updated_at":"2024-07-02T16:37:05.048Z","phase":"Phase 3","brief_title":"Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer","source_id_and_acronym":"NCT00087022","lead_sponsor":"Heidelberg Pharma AG","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rencarex (girentuximab)"],"overall_status":"Completed","enrollment":" Enrollment 864","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2018-11-27"}]